Gsk Shares | Buy

: The total 2025 dividend was 66p (up 8.2% from 2024). Management has signaled an expected increase to 70p for 2026.

: While long-term momentum is high, short-term technical indicators show a recent consolidation phase , with some analysts suggesting the stock is a "hold" or "reduce" candidate at current levels after hitting recent peaks.

: 2025 revenue hit £32.7bn (up 7%), driven by high-margin specialty medicines like HIV and Respiratory treatments. buy gsk shares

: Major product approvals are expected in 2026 for Bepirovirsen (Chronic Hepatitis B) and Tebipenem (UTIs).

Are you considering GSK primarily for its or for long-term growth in its oncology pipeline? : The total 2025 dividend was 66p (up 8

: The payout ratio sits at a healthy 38%–51% of earnings, suggesting the dividend is well-covered by cash flow. ⚠️ The Bear Case: Risks to Watch

AI responses may include mistakes. For financial advice, consult a professional. Learn more Why is everyone buying GSK shares? | The Motley Fool UK : 2025 revenue hit £32

🎯 : GSK is scheduled to report its Q1 2026 earnings on April 29, 2026 , with analysts expecting revenue of roughly $10.24 billion .